Cognitive disorders clinical trials

ELAN 301: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E4 Non-Carriers.

Patients are randomly chosen (by chance) to receive Bapineuzumab 1.0 mg/kg, Bapineuzumab 0.5 mg/kg, or placebo (normal saline) by infusion every 13 weeks. The study is approximately 83 weeks long with 15 visits.

Bapineuzumab is an investigational medication (not approved by the FDA). Patients must not be on cholinesterase inhibitors or memantine unless they have been receiving a stable dose of medication for at least 120 days prior.

Sponsor: Elan Pharmaceuticals Inc.
Principal investigator: Michael Mega, M.D., Ph.D.
If you are interested in this study, please contact Summer Carter, clinical research coordinator, at 503-216-1034.

Protocol CN156018: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer's Disease.

The duration of study includes a maximum 42-day screening period followed by 24 weeks of treatment and a 28-week follow-up period. Patients will initially take either two capsules (50 mg) of BMS-708163 a day or matching placebo for the first two weeks, and then take five capsules (125 mg) of BMS-708163 or matching placebo for the remainder of the 24-week treatment period. BMS-708163 is a potent, selective and orally-active ?-secretase inhibitor.

Sponsor: Bristol-Myers Squibb Research and Development
Principal investigator: Michael Mega, M.D., Ph.D.
If you are interested in this study, please contact Chad Parks, clinical research coordinator, at 503-216-2736.

Providence Brain and Spine Institute is involved in several clinical trials for investigational medications for Alzheimer's disease.

Latest news

View All